MedTrace Logo

Pattern Of Use Of Belatacept In US Transplant Recipients

NCT01670058 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 5000

Last updated 2018-07-13

No results posted yet for this study

Summary

* The prevalence of Belatacept use
* The characteristics of Belatacept users and the temporal trends in these characteristics
* Characteristics of adult kidney-only transplant recipients who are treated with Belatacept vs. who are treated with Calcineurin inhibitors (CNI)-based regimens at the time of transplantation, and the temporal trends in these characteristics during 7 years post approval of Belatacept.

Conditions

  • Kidney Transplantation: Transplantation, Kidney

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2018-06-12
Completion
2018-06-12

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01670058 on ClinicalTrials.gov